- Home
- RWAY vs CELC Comparison
RWAY vs CELC Comparison
Compare RWAY & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RWAY
- CELC
- Stock Information
- Founded
- RWAY 2015
- CELC 2011
- Country
- RWAY United States
- CELC United States
- Employees
- RWAY N/A
- CELC N/A
- Industry
- RWAY
- CELC Medical Specialities
- Sector
- RWAY
- CELC Health Care
- Exchange
- RWAY Nasdaq
- CELC Nasdaq
- Market Cap
- RWAY 395.5M
- CELC 409.7M
- IPO Year
- RWAY 2021
- CELC 2017
- Fundamental
- Price
- RWAY $9.94
- CELC $13.05
- Analyst Decision
- RWAY Buy
- CELC Strong Buy
- Analyst Count
- RWAY 6
- CELC 5
- Target Price
- RWAY $10.75
- CELC $30.80
- AVG Volume (30 Days)
- RWAY 364.2K
- CELC 142.6K
- Earning Date
- RWAY 05-12-2025
- CELC 05-14-2025
- Dividend Yield
- RWAY 12.07%
- CELC N/A
- EPS Growth
- RWAY 51.80
- CELC N/A
- EPS
- RWAY 1.67
- CELC N/A
- Revenue
- RWAY $140,021,000.00
- CELC N/A
- Revenue This Year
- RWAY N/A
- CELC N/A
- Revenue Next Year
- RWAY N/A
- CELC N/A
- P/E Ratio
- RWAY $5.97
- CELC N/A
- Revenue Growth
- RWAY N/A
- CELC N/A
- 52 Week Low
- RWAY $8.35
- CELC $7.58
- 52 Week High
- RWAY $12.17
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- RWAY 57.27
- CELC 73.94
- Support Level
- RWAY $9.61
- CELC $11.57
- Resistance Level
- RWAY $9.97
- CELC $12.34
- Average True Range (ATR)
- RWAY 0.20
- CELC 0.60
- MACD
- RWAY 0.01
- CELC 0.21
- Stochastic Oscillator
- RWAY 90.82
- CELC 94.26
About RWAY Runway Growth Finance Corp.
Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and Canada, with the majority of its portfolio invested in the United States.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.